International Clinical Trial: A Randomized, Open-Label, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study

Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07893002) titled 'A Randomized, Open-Label, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study' on Oct. 19.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).

Primary Sponsor: Sichuan Credit Pharmaceutical Co., Ltd.

Condition: Adjunct in the Treatment of Depressive Disorder

Intervention: Other: No intervention Dietary Supplement: CreNeuroST...